Adaptive Biotechnologies (ADPT) Could Be 6% Undervalued Following Its ClonoSEQ Growth Narrative

Simply Wall St.10-10

Adaptive Biotechnologies (ADPT) is back on watch after recent share price moves, with the stock last closing at US$26.49. Investors are reassessing the business as fresh performance data and valuation...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2674867603?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551728-choice1-card/1788934355557","is_english":true,"pubTime":"2026-10-10 06:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2674867603","market":"hk","top_or_hot":-1,"title":"Adaptive Biotechnologies (ADPT) Could Be 6% Undervalued Following Its ClonoSEQ Growth Narrative","media":"Simply Wall St.","content":"<div>\n<p>Adaptive Biotechnologies (ADPT) is back on watch after recent share price moves, with the stock last closing at US$26.49. Investors are reassessing the business as fresh performance data and valuation...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-could-be-6-undervalued-followi\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adaptive Biotechnologies (ADPT) Could Be 6% Undervalued Following Its ClonoSEQ Growth Narrative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdaptive Biotechnologies (ADPT) Could Be 6% Undervalued Following Its ClonoSEQ Growth Narrative\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-10 06:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-could-be-6-undervalued-followi><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Adaptive Biotechnologies (ADPT) is back on watch after recent share price moves, with the stock last closing at US$26.49. Investors are reassessing the business as fresh performance data and valuation...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-could-be-6-undervalued-followi\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-could-be-6-undervalued-followi","article_id":"2674867603","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551728-choice1-card/1788934355557"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-could-be-6-undervalued-followi","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2674867603","pubTimestamp":1791585261,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Adaptive Biotechnologies (ADPT) is back on watch after recent share price moves, with the stock last closing at US$26.49. Investors are reassessing the business as fresh performance data and valuation signals come into focus.\nRecent trading has been choppy. Adaptive Biotechnologies has a 1 day share price return of 1.53%, a 7 day share price return down 6.56%, a 90 day share price return of 25.78%, and a year to date share price gain of 66.50%. The company also has a 1 year total shareholder...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","ADPT":"Adaptive Biotechnologies Corp","HELX":"Franklin Genomic Advancements ETF"},"translate_title":"Adaptive Biotechnologies (ADPT) 的 ClonoSEQ 增长故事可能被低估 6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADPT":1.5,"HELX":0.6},"content_text":"Adaptive Biotechnologies (ADPT) is back on watch after recent share price moves, with the stock last closing at US$26.49. Investors are reassessing the business as fresh performance data and valuation signals come into focus. Recent trading has been choppy. Adaptive Biotechnologies has a 1 day share price return of 1.53%, a 7 day share price return down 6.56%, a 90 day share price return of 25.78%, and a year to date share price gain of 66.50%. The company also has a 1 year total shareholder return of 74.62% and a 3 year total shareholder return of more than 5x, which signals strong longer term momentum despite shorter term pullbacks. Scan how Adaptive Biotechnologies stacks up against other high momentum health and tech plays by reviewing our hand picked 20 high quality undiscovered gems in this corner of the market. After a sharp rebound and a last close of US$26.49, Adaptive Biotechnologies now trades only modestly below analyst targets but at a premium to some intrinsic estimates. Where does fair value realistically sit within that spread? AdvertisementMost Popular Narrative: 6% Undervalued At a last close of $26.49, the most followed narrative pegs Adaptive Biotechnologies fair value at $28.31, leaving a small valuation gap that rests on how its cancer testing franchise scales and gets paid for.  Accelerating integration of clonoSEQ into electronic medical records (EMRs) across both academic and community settings, as well as the major rollout with Flatiron's OncoEMR and expansion through partnerships like NeoGenomics, streamlines ordering and supports recurring test usage. This integration is expected to drive strong multi-year clinical volume growth and recurring revenue.  See why 8 investors see Adaptive Biotechnologies as 6% undervalued. Result: Fair Value of $28.31 (UNDERVALUED) Still, if CMS reimbursement decisions or key partnerships such as Genentech or NeoGenomics disappoint, that could quickly undermine the current Adaptive Biotechnologies narrative. Find out about the key risks to this Adaptive Biotechnologies narrative. Another View: What Multiples Say About Adaptive Biotechnologies The story looks different once you step away from analyst targets and look at plain P/S math. Adaptive Biotechnologies trades at a P/S of 13.7x, compared with 4.4x for the US Life Sciences group and a fair ratio of 5.1x that the market could move toward. That premium signals meaningful valuation risk if expectations cool rather than the clean 6% upside suggested by the consensus target. Which lens do you trust more when you weigh your next move? See what the numbers say about this price in our valuation breakdown, then pressure test your own view of Adaptive Biotechnologies using that context See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:ADPT P/S Ratio as at Oct 2026Next Steps If this mix of enthusiasm and concern feels familiar, take it as a cue to act promptly and evaluate the trade off for yourself using the 2 key rewards and 1 important warning sign. Looking for more investment ideas beyond Adaptive Biotechnologies? If Adaptive Biotechnologies has your attention, do not stop there. Use Simply Wall Street’s screeners to quickly surface other opportunities before they move without you.  Target potential value by scanning companies that combine quality fundamentals with pricing that still looks appealing using our 28 high quality undervalued stocks. Focus on staying power and peace of mind by reviewing a 31 resilient stocks with low risk scores that filters for resilience and lower overall risk profiles. Balance potential return with financial resilience by concentrating on businesses with healthier funding and cleaner accounts in our list of solid balance sheet and fundamentals (25 results).   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2674867603","isCrawlerRequest":true}